Trial reportBlood2014
Moderate-dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution.
Trial report in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01193283 (Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia
Who cites it
19 citing papers in PubMed, 48 citations in OpenAlex.
- Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemia.Frontiers in immunology · 2026Trial
- Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.British journal of haematology · 2021Trial
- Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia.The New England journal of medicine · 2017Trial
- Adverse events associated with cyclophosphamide: A pharmacovigilance study using the FDA adverse event reporting system.PloS one · 2026Article
- Umbilical cord blood infusion in the treatment of aplastic anemia: A single center prospective study.Scientific reports · 2025Article
- Up-front alternative donor HCT in severe aplastic anemia: gaps and opportunities to translate evidence into practice.Blood advances · 2025Review
- Human autoimmunity at single cell resolution in aplastic anemia before and after effective immunotherapy.Nature communications · 2025Article
- Long-term eltrombopag for bone marrow failure depletes iron.American journal of hematology · 2022Article
- Dietary restriction increases protective gut bacteria to rescue lethal methotrexate-induced intestinal toxicity.Gut microbes · 2020Article
- [How I treat refractory sever aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2020Article
- Aplastic anemia and COVID-19: how to break the vicious circuit?American journal of blood research · 2020Article
- Activity of eltrombopag in severe aplastic anemia.Hematology. American Society of Hematology. Education Program · 2018Review
- Activity of eltrombopag in severe aplastic anemia.Blood advances · 2018Review
- Diagnosis and Treatment of Aplastic Anemia.Current treatment options in oncology · 2017Review
- Recent advances in understanding clonal haematopoiesis in aplastic anaemia.British journal of haematology · 2017Review
- Nontransplant therapy for bone marrow failure.Hematology. American Society of Hematology. Education Program · 2016Review
- Acquired aplastic anemia in Korean children: treatment guidelines from the Bone Marrow Failure Committee of the Korean Society of Pediatric Hematology Oncology.International journal of hematology · 2016Review
- [Advances in the treatment of severe aplastic anemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2015Article
- The diagnosis and treatment of aplastic anemia: a review.International journal of hematology · 2015Review
Corrections and comments
- Commented on by
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
First-line therapy of severe aplastic anemia (SAA) with high-dose cyclophosphamide causes toxicity and increased short-term mortality. We investigated cyclophosphamide at a lower, more moderate dose in combination with aggressive supportive care to determine whether severe infections might be avoided and hematologic outcomes defined for this regimen. From 2010 to 2012, 22 patients received cyclophosphamide at 120 mg/kg plus cyclosporine and antibacterial, antiviral, and antifungal prophylaxis. Toxicity was considerable, mainly due to prolonged absolute neutropenia, which occurred regardless of pretherapy blood counts, and persisted an average of 2 months. Granulocyte transfusions for uncontrolled infection were required in 5 patients, confirmed fungal infections were documented in 6, and 9 patients died. Nine patients (41%) responded at 6 months. After a median follow-up of 2.2 years, relapse occurred in 2 patients, and cytogenetic abnormalities (including monosomy 7) were observed in 4 patients. Although cyclophosphamide has activity in SAA, its toxicity is not justified when far less dangerous alternatives are available. This trial was registered at www.clinicaltrials.gov as #NCT01193283.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.